Hyperkalemia, renal failure, and converting-enzyme inhibition: an overrated connection
| Autor: | Sandra T. Baigorria, Luis I. Juncos, Néstor H. García |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Male
Hypertension Renal Hyperkalemia medicine.medical_treatment Angiotensin-Converting Enzyme Inhibitors Kidney Nephrectomy Rats Sprague-Dawley chemistry.chemical_compound Tetrahydroisoquinolines Renal Insufficiency Aldosterone Aged 80 and over Middle Aged Creatinine Female medicine.symptom medicine.drug Glomerular Filtration Rate Adult medicine.medical_specialty Adolescent medicine.drug_class Urology Peptidyl-Dipeptidase A Internal medicine Internal Medicine medicine Animals Humans Aged Retrospective Studies Uremia business.industry Quinapril medicine.disease Isoquinolines Rats Disease Models Animal Endocrinology chemistry Potassium-sparing diuretic ACE inhibitor Spironolactone Potassium business Kidney disease |
| Zdroj: | Hypertension (Dallas, Tex. : 1979). 38(3 Pt 2) |
| ISSN: | 1524-4563 |
| Popis: | Abstract — — Hyperkalemia is widely viewed as a common complication of ACE inhibition in azotemic patients. These renal failure patients are the patients who benefit most from ACE inhibition. Because we could not confirm this notion after a retrospective evaluation of 236 azotemic patients, we studied 2 models of renal mass reduction. In the first, we did a 5/6 nephrectomy (Nx) on rats and studied them 2 weeks after surgery (before chronic renal changes had developed). A second group was studied 16 weeks after Nx, once chronic renal failure was established. Rats in both models were treated with quinapril in drinking water. After baseline evaluation, we challenged them either by a high-K + diet or by blocking aldosterone receptors. We found that although quinapril blocked the K + -induced increase in aldosterone, serum K + levels and K + balance were maintained before and during high K + intake or during simultaneous spironolactone administration. We conclude that in hemodynamically stable rats with reduced renal mass and renal dysfunction, the administration of an ACE inhibitor does not cause severe hyperkalemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|